Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 20/20 | 0.62 |
| ▸ | SLC6A3 known ✓ | Q01959 | 11/20 | 0.62 |
| ▸ | SLC6A4 known ✓ | P31645 | 7/20 | 0.57 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3594667 | 0.99 | SLC6A2 (0.63) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL3604891 | 0.90 | SLC6A2 (0.51) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| SCHEMBL3592065 | 0.89 | SLC6A2 (0.73) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| SCHEMBL3608467 | 0.88 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL3607600 | 0.87 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL4945774 | 0.87 | SLC6A2 (0.78) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL3596657 | 0.87 | SLC6A2 (0.55) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| SCHEMBL3594671 | 0.86 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| SCHEMBL3595485 | 0.85 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4KCNH2 | |
| SCHEMBL4055154 | 0.85 | SLC6A2 (0.80) | SLC6A2SLC6A3SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101595106-B | Substituted gamma lactams as therapeutic agents | ALLERGAN INC | 2014-05-07 | — | — | CN | disclosed |
| CN-101868455-B | Therapeutic substituted lactams | ALLERGAN INC | 2013-11-13 | — | — | CN | disclosed |
| CN-101795692-B | Therapeutic substituted cyclopentanes for reducing intraocular pressure | OLD DAVID W | 2013-06-12 | — | — | CN | disclosed |
| CN-101657445-B | Gamma-lactams for the treatment of glaucoma or elevated intraocular pressure | ALLERGAN INC | 2013-06-05 | — | — | CN | disclosed |
| CN-101522669-B | Therapeutic lactams | ALLERGAN INC | 2013-01-16 | — | — | CN | disclosed |
| CN-102089295-A | Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds | ALLERGAN INC | 2011-06-08 | — | — | CN | disclosed |
| CN-102089285-A | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN INC | 2011-06-08 | — | — | CN | disclosed |
| CN-102083807-A | Therapeutic compounds | ALLERGAN INC | 2011-06-01 | — | — | CN | disclosed |
| CN-101868455-A | Therapeutic substituted lactams | ALLERGAN INC | 2010-10-20 | — | — | CN | disclosed |
| CN-101795692-A | Therapeutic substituted cyclopentanes for reducing intraocular pressure | OLD DAVID W | 2010-08-04 | — | — | CN | disclosed |
| CN-101595106-A | Gamma-lactams as the replacement of medicine | ALLERGAN INC (US) | 2009-12-02 | — | — | CN | disclosed |
| US-7601722-B2 | Aryl sulfamide derivatives and methods of their use | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| CN-101522669-A | Therapeutic lactams | ALLERGAN INC (US) | 2009-09-02 | — | — | CN | disclosed |
| EP-2061776-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | Wyeth a Corporation of the State of Delaware (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-2054409-A2 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS | Allergan, Inc. (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080167303-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008024765-A2 | THERAPEUTIC SUBSTITUTED THIAZOLIDINONES, OXAZOLIDINONES, AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| CN-1842516-A | Amide compounds and method for controlling plant diseases using the same | SUMITOMO CHEMICAL CO (JP) | 2006-10-04 | — | — | CN | disclosed |
| CN-1301305-A | Serine protease variants with amino acid substitutions | PROCTER & GAMBLE (US) | 2001-06-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167303-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | SLC6A2 2/4885SLC6A3 3/4885SLC6A4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.